Press Releases

Date Title
2/15/10 AVI BioPharma Receives Grants Totaling $500,000 from CureDuchenne and the Foundation to Eradicate Duchenne to Support Continuing Development of Drug Candidates to Treat Duchenne Muscular Dystrophy
2/5/10 AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation For Duchenne Muscular Dystrophy
2/4/10 AVI BioPharma GLP Safety Pharmacology and Genotoxicity Evaluations of AVI-4658 for Duchenne Muscular Dystrophy Published in the International Journal of Toxicology
1/15/10 TMTI Accomplishments Have Advanced the Nation's Ability to Successfully Counter an Emerging Biothreat
12/22/09 Systemic Treatment with AVI-4658 Demonstrates RNA Exon Skipping and Dystrophin Protein Expression in Duchenne Muscular Dystrophy Patients
11/19/09 AVI BioPharma, Inc. Presents Update on AVI-4658 at TREAT-NMD / NIH International Conference
11/18/09 AVI BioPharma, Inc. to Present at Transformational Medical Technologies Initiative (TMTI) Industry Day
11/9/09 AVI BioPharma Announces Third Quarter 2009 Financial Results & Corporate Highlights
11/2/09 AVI BioPharma Announces Third Quarter 2009 Financial Results Conference Call
10/26/09 AVI BioPharma Presents Updated Safety Data from Ongoing Systemic Trial of AVI-4658 at 7th Annual Action Duchenne International Conference
Displaying 641 - 650 of 813